TP53 and leukemia: In AML, p53 mutations have been almost exclusively found in patients with unfavorable complex karyotype or therapy-related AML.4, 5 In addition, p53 mutation is itself an independent predictor of extremely poor outcome.6 Therefore, PTC596 deserves further evaluation in clinical trials for refractory or relapsed AML, regardless of the presence of unfavorable karyotype or p53 mutations in leukemia blasts.